Femasys prices $8 million public offering to fund growth initiatives

ATLANTA - Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on women’s health with a market capitalization of $16.8 million, announced Monday the pricing of an underwritten public offering expected to raise approximately $8 million in gross proceeds. According to InvestingPro data, the company has been rapidly burning through cash, making this offering crucial for its operations.

The offering consists of 10,434,586 shares of common stock and pre-funded warrants to purchase up to 11,750,000 shares, along with accompanying common warrants to purchase up to 22,184,586 shares. The combined public offering price is $0.36 per share and accompanying warrant, with a small portion sold to company officers at $0.5151 per unit.

The common warrants will be immediately exercisable upon issuance with a five-year term. Jones and Laidlaw & Company (UK) Ltd. are serving as joint book-running managers for the offering, which is expected to close around Wednesday, subject to customary closing conditions.

Femasys plans to use the proceeds to expand commercial efforts, develop its product portfolio, and fund general corporate expenses. The company manufactures and markets fertility and non-surgical birth control products, including FemaSeed Intratubal Insemination and FemVue diagnostic for fallopian tube assessment. Despite current challenges, the company maintains a healthy gross profit margin of 65% and analysts expect significant revenue growth in the coming year. InvestingPro subscribers have access to 15+ additional insights about Femasys’s financial health and growth prospects.

The company’s FemBloc permanent birth control, a non-surgical alternative to traditional sterilization, received regulatory approval in Europe in June 2025 and in the UK in August 2025. A pivotal trial for U.S. FDA approval is currently ongoing.

The securities are being offered pursuant to a Registration Statement on Form S-1 previously filed with and declared effective by the SEC on Monday.

This article is based on information from a company press release statement.

In other recent news, Femasys Inc. announced it has received approval from the UK’s Medicines and Healthcare products Regulatory Agency for its FemBloc Permanent Birth Control system. This follows the company’s earlier achievement of obtaining the CE mark certification in Europe. Femasys also reported receiving its first European commercial order for FemBloc from distribution partners in Spain, valued at approximately $400,000. This order marks Femasys’ initial commercial entry into the European market, with Spain being the first country to offer this non-surgical permanent contraceptive option. In other developments, Femasys received a notification from The Nasdaq Stock Market regarding noncompliance with the minimum bid price requirement, although this does not immediately affect the listing or trading of its stock. The company has been given a 180-day grace period to regain compliance. Additionally, Femasys appointed Kelley Nicholas as Chief Commercial Officer to lead its commercial strategy and drive revenue growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.